OBJECTIVE: To perform health technology assessment（ HTA） based on the safety

effectiveness and economy of caspofungin in the prevention and treatment of invasive fungal diseases

so as to provide evidence-based basis for clinical rational drug use and decision-making at all levels. METHODS: PubMed

EMBase

the Cochrane Library

CNKI

Wanfang database

VIP database and official website of domestic and foreign HTA institutions were retrieved to collect HTA report

systematic review/Meta-analysis and pharmacoeconomic studies on the prevention or treatment of invasive fungal infection with capofungine compared with other positive drugs or combination drugs.Statistical analysis was performed on the included literature. RESULTS & CONCLUSIONS: Fourteen Meta analyses and22 pharmacoeconomic studies were included. In the treatment or prevention of invasive fungal infection

caspofunnet had higher safety and better effectiveness than other antifungal agents. In most developed countries（ such as the United States

the United Kingdom

France

Germany

Italy

Australia）

caspofunnet had cost-effectiveness advantage. In the pharmacoeconomics studies carried out in China

caspofungin is more economical than voriconazole in the initial empirical antifungal treatment of patients with agranulocytosis and fever. In the prevention and treatment of invasive fungal infection

fluconazole and micafungin are more economical than caspofungin. For the economic evaluation of caspofungin in China

more in-depth and large-scale studies are needed to support the decision-making.